share_log

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $5

Benzinga Real-time News ·  Aug 17, 2022 10:34

Lake Street analyst Frank Takkinen maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $7 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment